A detailed history of King Luther Capital Management Corp transactions in Exact Sciences Corp stock. As of the latest transaction made, King Luther Capital Management Corp holds 32,645 shares of EXAS stock, worth $1.41 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
32,645
Previous 32,780 0.41%
Holding current value
$1.41 Million
Previous $2.43 Million 7.05%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$56.27 - $73.77 $7,596 - $9,958
-135 Reduced 0.41%
32,645 $2.25 Million
Q4 2023

Feb 09, 2024

BUY
$59.06 - $75.72 $590 - $757
10 Added 0.03%
32,780 $2.43 Million
Q3 2023

Nov 13, 2023

SELL
$65.94 - $99.04 $18,661 - $28,028
-283 Reduced 0.86%
32,770 $2.24 Million
Q2 2023

Aug 10, 2023

BUY
$62.68 - $95.05 $20,559 - $31,176
328 Added 1.0%
33,053 $3.1 Million
Q1 2022

May 11, 2022

BUY
$57.56 - $82.54 $1.88 Million - $2.7 Million
32,725 New
32,725 $2.29 Million
Q1 2021

May 12, 2021

SELL
$116.57 - $155.01 $775,190 - $1.03 Million
-6,650 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$72.92 - $102.01 $60,523 - $84,668
830 Added 14.26%
6,650 $678,000
Q2 2020

Aug 12, 2020

SELL
$55.75 - $92.75 $6,690 - $11,130
-120 Reduced 2.02%
5,820 $506,000
Q1 2020

May 13, 2020

SELL
$37.9 - $104.44 $12,317 - $33,943
-325 Reduced 5.19%
5,940 $345,000
Q4 2019

Feb 12, 2020

SELL
$77.66 - $99.74 $3,494 - $4,488
-45 Reduced 0.71%
6,265 $579,000
Q1 2019

May 10, 2019

SELL
$61.98 - $96.5 $58,881 - $91,675
-950 Reduced 13.09%
6,310 $547,000
Q3 2018

Nov 13, 2018

BUY
$48.29 - $80.6 $350,585 - $585,156
7,260 New
7,260 $573,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $7.64B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track King Luther Capital Management Corp Portfolio

Follow King Luther Capital Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of King Luther Capital Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on King Luther Capital Management Corp with notifications on news.